Dr. Alaa Darkazally | Gastric Cancer | Best Researcher Award

Dr. Alaa Darkazally | Gastric Cancer | Best Researcher Award

Damascus University | Syria

Author Profile

ORCID Id

📊Dr. Alaa Darkazally

📍 Pharmacist | Academic Supervisor | Researcher
🌍 Damascus, Syria

📍Summary

Dr. Alaa Darkazally is a dedicated pharmacist and academic supervisor with extensive experience across pharmaceutical industries, academia, and humanitarian sectors. With a strong academic background, including a Master’s in Pharmacology from Damascus University and ongoing studies towards a Master’s in Medical Education at the Syrian Virtual University, Dr. Darkazally combines academic expertise with practical experience in pharmacy and healthcare.

🌍Professional Experience

💼Volunteer Work

  • Volunteer at Saiyar Project (September 2022 – Present)
    • Contributing to voluntary actions in various community initiatives.

    Volunteer at Samma3t Hakeem (February 2022 – Present)

    • Applying pharmaceutical expertise in humanitarian work.

    Volunteer at A+ Pharmacists Team (July 2022 – January 2023)

    • Gaining experience in scientific research and promoting knowledge exchange.

🌐Education

  • Master in Medical Education (in progress), Syrian Virtual University (2026 expected)
  • Master’s in Pharmacology, Damascus University (2023)
  • Bachelor’s Degree in Pharmacy and Pharmaceutical Industries, Damascus University (2017)

🎯Skills

  • 💼 Microsoft Word, PowerPoint, Excel
  • 🎯 Leadership, Critical Thinking, Problem-Solving, Communication Skills
  • 🌐 Arabic (Native), English (Excellent), French (Beginner)

Conclusion

With a strong commitment to education and community service, this professional continuously seeks opportunities to grow and contribute positively to their organization. Their extensive background in pharmacy and education, combined with their dedication to humanitarian efforts, positions them as a valuable asset in any healthcare or academic setting. 🌟

📊🔬NOTABLE PUBLICATION:

    • “Troxerutin effect on gastric ulcers induced by ketorolac in rats: Relation with oxidative stress”:
      • Authors: Alaa Zouher Darkazally, Amirah Alnour, Shadi Homsi
      • Journal: Heliyon
      • Year: 2024

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION: